Palonosetron (Aloxi)

Isoquinoline and quinuclidine derivative that acts as a 5-HT3 RECEPTOR antagonist. It is used in the prevention of nausea and vomiting induced by cytotoxic chemotherapy, and for the prevention of post-operative nausea and vomiting.

Also Known As:

Aloxi; 2-(1-azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one; 2-QHBIQO; Palonosetron Hydrochloride; Palonosetron, (3R)-; Palonosetron, (R-(R*,R*))-isomer; Palonosetron, (R-(R*,S*))-isomer; Palonosetron, (S-(R*,S*))-isomer; RS 25233-197; RS 25233-198; RS 25259; RS 25259-197; RS 25259-198; RS-25233-197; RS-25233-198; RS-25259; RS-25259-197; RS-25259-198; RS 25233 197; RS 25233 198; RS 25233197; RS 25233198; RS 25259 197; RS 25259 198; RS 25259197; RS 25259198; RS25233197; RS25233198; RS25259; RS25259197; RS25259198; 1H-Benz(de)isoquinolin-1-one, 2-((3S)-1-azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-, (3aS)-

Networked: 550 relevant articles (179 outcomes, 241 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 207
- Bridged-Ring Heterocyclic Compounds
  - Quinuclidines: 20
    - Palonosetron: 550
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 37
      - Palonosetron: 550

Experts

1.	Celio, Luigi: 22 articles (03/2024 - 07/2008)
2.	Aapro, Matti: 17 articles (03/2024 - 01/2004)
3.	Bonizzoni, Erminio: 10 articles (01/2023 - 02/2013)
4.	Darmani, Nissar A: 10 articles (06/2021 - 01/2014)
5.	Zhong, Weixia: 10 articles (06/2021 - 01/2014)
6.	Navari, Rudolph M: 10 articles (10/2019 - 11/2007)
7.	Schwartzberg, Lee: 10 articles (04/2019 - 02/2006)
8.	Rojas, Camilo: 9 articles (12/2015 - 12/2007)
9.	Karthaus, Meinolf: 8 articles (04/2022 - 01/2015)
10.	Chebolu, Seetha: 8 articles (06/2021 - 01/2014)

Related Diseases

1.	Vomiting 02/01/2024 - "There was a significant improvement in the scores of Functional Living Index-Emesis in patients using palonosetron." 07/01/2014 - "In conclusion, palonosetron and first-generation 5-HT3 RAs were at least equally effective in emesis prophylaxis for allo-HSCT recipients. " 01/01/2018 - "The efficacy of palonosetron in preventing emesis was evaluated in 40 patients. " 08/01/2014 - "However, palonosetron has also shown consistent improvement in the suppression of delayed emesis. " 02/01/2024 - "The incidence of complete response and proportion of patients with higher Functional Living Index-Emesis scores were significantly higher in patients using palonosetron. "
2.	Nausea 02/01/2015 - "Along with a more complete response, the severity of nausea was also lesser with palonosetron during the corresponding study periods (2-24 and 24-48 h, respectively; p < 0.05). " 05/01/2024 - "In the palonosetron group, patients with the GG genotype (rs16947 A/G) experienced more severe nausea (p = 0.043). " 01/01/2023 - "Palonosetron ocular drops at the dose of 30 µg/kg reduced cumulative nausea over time as measured with the area under the visual analog scale curve by 98% compared with the vehicle and reduced nausea-associated dog behavior by 95%. " 01/01/2020 - "A significantly higher number of patients in the palonosetron arm were free from nausea during the delayed phase (28% vs 40.1%; P = .029). " 01/01/2018 - "The severity of nausea was lower in the palonosetron group (p = 0.010). "
3.	Postoperative Nausea and Vomiting (PONV) 01/01/2022 - "When it comes to the prevention of early PONV, it has been shown that palonosetron is more effective than other medications. " 01/01/2020 - "Palonosetron is effective for PONV prevention at the usual dose of 75 μg, but the ideal dose for obese patients has not yet been investigated. " 02/01/2015 - "A prospective, randomized, double-blind, multicenter trial to evaluate the therapeutic efficacy and safety of palonosetron in the treatment of postoperative nausea and vomiting over a 72-h period." 10/01/2015 - "The data showed statistically significant differences in favor of palonosetron (0.075 mg) in the prevention of acute PONV (P < .00001) and delayed PONV (P < .002), reducing the risk of PONV by 49% and 51%, respectively. " 03/01/2014 - "Efficacy of palonosetron for the prevention of postoperative nausea and vomiting: a randomized, double-blinded, placebo-controlled trial."
4.	Neoplasms (Cancer) 07/01/2012 - "The second-generation 5-HT(3) antagonist palonosetron is highly effective in preventing CINV in patients with solid tumors. " 09/01/2018 - "A multicenter, single-arm, open-label phase II trial was conducted to evaluate the safety and effectiveness of palonosetron in controlling CINV in patients with gynecologic cancer. " 10/01/2012 - "The purpose of this study is to determine acute effects of palonosetron on electrocardiographic (ECG) parameters in cancer patients. " 01/01/2011 - "We identified randomized controlled clinical trials (RCT) comparing palonosetron with first-generation 5-HT3RA in the prevention of CINV in cancer patients. " 10/01/2012 - "Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study."
5.	Breast Neoplasms (Breast Cancer) 05/01/2012 - "Patients with lung or breast cancer receiving MEC or HEC had significantly lower risk of CINV events associated with hospital/ED admissions if initiated and maintained on palonosetron relative to patients receiving 5-HT(3) RA regimens." 11/01/2010 - "Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients." 06/01/2017 - "Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials." 05/01/2010 - "Double-blind, multicentre, noninferiority study of chemotherapy-naive breast cancer patients receiving 0.25 mg palonosetron and 8 mg dexamethasone on day 1, randomly assigned to receive placebo (n = 151) or 4 mg b.i.d. " 02/01/2013 - "Chemo-naïve breast cancer patients randomized to receive palonosetron (0.25 mg) plus dexamethasone (8 mg IV) on day 1 of chemotherapy (n = 200), or the same regimen followed by oral dexamethasone (8 mg) on days 2 and 3 (n = 205), were included in the analysis. "

Related Drugs and Biologics

1.	Dexamethasone (Maxidex)
2.	Antiemetics
3.	Aprepitant (Emend)
4.	Cisplatin (Platino)
5.	netupitant
6.	Granisetron (Kytril)
7.	Ondansetron (Zofran)
8.	ramosetron (Nasea)
9.	5-HT3 Serotonin Receptors (5 HT3 Receptor)
10.	Serotonin (5 Hydroxytryptamine)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	General Anesthesia
4.	Laparoscopic Cholecystectomy
5.	Patient-Controlled Analgesia (Analgesia, Patient Controlled)